Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 08, 2025 10:00 ET | Source: Precedence Research

Stem Cell Therapy Market Attains USD 4,777.4 Mn Driving at 25.26% CAGR by 2034

Ottawa, Sept. 08, 2025 (GLOBE NEWSWIRE) -- The global stem cell therapy market size was estimated at USD 490 million in 2024 and is forecasted to reach approximately USD 4,777.4 million by 2034,...
April 28, 2025 08:00 ET | Source: Calidi Biotherapeutics, Inc

Calidi Biotherapeutics Announces IL15 Superagonist as First Payload to be Delivered by Systemic Antitumor Virotherapy Platform at AACR Annual Meeting

SAN DIEGO, April 28, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor...
April 25, 2025 08:00 ET | Source: Calidi Biotherapeutics, Inc

Calidi Biotherapeutics Reports Inducement Grant Under NYSE American LLC Company Guide Section 711

SAN DIEGO, April 25, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor...
April 23, 2025 08:00 ET | Source: Calidi Biotherapeutics, Inc

Calidi Biotherapeutics Announces Chief Executive Officer Transition and Appointment of Eric Poma, Ph.D. as CEO and Director

SAN DIEGO, April 23, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor...
April 22, 2025 08:00 ET | Source: Calidi Biotherapeutics, Inc

Join Calidi Biotherapeutics’ Exclusive Live Investor Webinar and Q&A Session on April 24

SAN DIEGO, April 22, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor...
April 17, 2025 08:00 ET | Source: Calidi Biotherapeutics, Inc

Calidi Biotherapeutics Announces FDA Clearance of IND Application for CLD-201 in Solid Tumors

SAN DIEGO, April 17, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company pioneering targeted antitumor virotherapies,...
March 31, 2025 16:10 ET | Source: Calidi Biotherapeutics, Inc

Calidi Biotherapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Operational Highlights

Announced demonstrated ability to deliver transient gene therapy (payload) to tumors using systemic antitumor virotherapy platform Filed IND in March 2025 for CLD-201 company sponsored Phase 1 trial...
March 28, 2025 09:00 ET | Source: Calidi Biotherapeutics, Inc

Calidi Biotherapeutics Announces Pricing of $3.9 Million Registered Direct Offering and Concurrent Private Placement

SAN DIEGO, March 28, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company developing a new generation of...
March 26, 2025 08:00 ET | Source: Calidi Biotherapeutics, Inc

Calidi Biotherapeutics and City of Hope Provide Update on a Phase 1 Clinical Trial with CLD-101 Virotherapy in Patients with Recurrent High-Grade Glioma

SAN DIEGO and LOS ANGELES, March 26, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of...
February 24, 2025 08:00 ET | Source: Calidi Biotherapeutics, Inc

Calidi Biotherapeutics Announces Commencement of Recruitment for Multiple Dose CLD-101 Trial in Patients with Newly Diagnosed High Grade Glioma at Northwestern University Hospital

SAN DIEGO, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor...